Table 1.
Characteristics of patients
| Characteristics | DEB-TACE (N = 40) | cTACE (N = 49) | P value |
|---|---|---|---|
| Age (years), mean±SD | 61.8±10.7 | 57.4±10.4 | 0.053 |
| Gender, No. (%) | 0.608 | ||
| Male | 25 (62.5) | 28 (57.1) | |
| Female | 15 (37.5) | 21 (42.9) | |
| HBV, No. (%) | 3 (7.5) | 5 (10.2) | 0.943 |
| ECOG PS score, No. (%) | 0.722 | ||
| 0 | 17 (42.5) | 19 (38.8) | |
| 1 | 23 (57.5) | 30 (61.2) | |
| Child-Pugh stage, No. (%) | 0.322 | ||
| A | 35 (87.5) | 39 (79.6) | |
| B | 5 (12.5) | 10 (20.4) | |
| Tumor number, No. (%) | 0.512 | ||
| Single | 16 (40.0) | 23 (46.9) | |
| Multiple | 24 (60.0) | 26 (53.1) | |
| Tumor size (cm), mean±SD | 7.9±6.6 | 7.0±4.1 | 0.410 |
| Lymph node metastasis, No. (%) | 31 (77.5) | 29 (59.2) | 0.744 |
| Ascites, No. (%) | 3 (7.5) | 4 (8.2) | 0.999 |
| Biochemical indexes | |||
| ALT (U/L), mean±SD | 41.8±53.2 | 49.8±45.7 | 0.454 |
| Albumin (g/L), mean±SD | 35.5±5.1 | 35.8±10.5 | 0.375 |
| Bilirubin (umol/L), mean±SD | 19.8±6.3 | 19.3±4.7 | 0.452 |
| PT (s) , mean±SD | 13.9±2.1 | 13.7±1.9 | 0.534 |
| Neutrophile (x109/L), mean±SD | 5.0±2.1 | 4.3±2.1 | 0.143 |
| Lymphocyte (x109/L), mean±SD | 1.1±0.5 | 1.5±0.6 | 0.002 |
| PLT (x109/L), mean±SD | 188.8±86.0 | 190.4±84.7 | 0.931 |
| CA125 (U/mL), mean±SD | 131.5±204.8 | 121.8±273.3 | 0.853 |
| CA199 (U/mL), mean±SD | 518.4±525.7 | 528.5±1722.0 | 0.972 |
| TACE session, No. (%) | 0.741 | ||
| 1 | 19 (47.5) | 25 (51.0) | |
| ≥2 | 21 (52.5) | 24 (49.0) | |
| Previous treatments | |||
| Surgery, No. (%) | 8 (20.0) | 18 (36.7) | 0.084 |
| Radiofrequency ablation, No. (%) | 0(0) | 0(0) | - |
| Systematic chemotherapy, No. (%) | 4 (10.0) | 6 (12.2) | 0.739 |
| Targetded therapy, No. (%) | 0 (0) | 0 (0) | - |
| PTCD/MRCP, No. (%) | 9 (22.5) | 15 (30.6) | 0.391 |
DEB-TACE, drug-eluting beads transarterial chemoembolization; cTACE, conventional transarterial chemoembolization; SD, standard deviation; HBV, hepatitis B virus; ECOG PS, Eastern Cooperative Oncology Group Performance Status; ALT, alanine aminotransferase; PT, Prothrombin time; PLT, blood platelet; CA125, carbohydrate antigen 125; CA199, carbohydrate antigen 199; PTCD, percutaneous transhepatic cholangial drainage; MRCP, magnetic resonance cholangiopancreatography.